Influenza vaccine quadrivalent - Seqirus

Drug Profile

Influenza vaccine quadrivalent - Seqirus

Alternative Names: Afluria Quad; AFLURIA QUADRIVALENT; CSL QIV; Quadrivalent influenza vaccine - Seqirus; Quadrivalent-influenza-vaccine-(CSL-QIV); Seqirus QIV

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator bioCSL
  • Developer Seqirus
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 18 Sep 2017 Launched for Influenza virus infections (Prevention, In children, In adolescents) in USA (IM)
  • 14 Sep 2017 Registered for Influenza virus infections (In adolescents, In children, Prevention) in USA (IM)
  • 17 Aug 2017 Seqirus completes a phase III non-inferiority trial for Influenza virus infections (Prevention, In infants, In children) in USA (IM) (NCT02914275)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top